Immunotherapy: a New Approach of Cancer Treatment

THIS MATERIAL IS A MARKETING COMMUNICATION.

Immunotherapy: a New Approach of Cancer Treatment

Immunotherapy is a type of oncology treatment that helps the immune system fight cancer. The immune system helps the body fight infections and other diseases. Immunotherapy is a type of biological therapy. Biological therapy is a type of treatment that uses substances made of living organisms to treat cancer.

Immuno-oncology therapy, including checkpoint inhibitors, therapeutic cancer vaccines, cytokines and cell therapies, has revolutionized cancer treatment in the past few years. There is still significant room for improvement in immuno-oncology therapy’s efficacy and safety. Continued research and development efforts are underway around the world, with a focus on characterizing novel immuno-oncology targets and exploring combination therapies.

Given the substantial number of cancer patient population in China and the US, the global market size for immuno-oncology therapies is projected to continue growth at a substantial rate both domestically in China and abroad.

Several types of immunotherapy are used to treat cancer. These include:

  • Immune checkpoint inhibitors, which are drugs that block immune checkpoints. These checkpoints are a normal part of the immune system and keep immune responses from becoming too strong. By blocking them, these drugs allow immune cells to respond more powerfully against cancer.
  • T-cell transfer therapy, which is a treatment that boosts the natural ability of T cells to fight cancer. Those that are most active against cancer are selected or modified in the lab to better attack cancer cells.
  • Monoclonal antibodies, which are immune system proteins created in the lab, are designed to bind to specific targets on cancer cells. Some monoclonal antibodies mark cancer cells so that they can be better identified and destroyed by the immune system.
  • Treatment vaccines, which work against cancer by boosting the immune system’s response to cancer cells. Treatment vaccines are different from the ones that help prevent disease.
  • Immune system modulators, enhance the body’s immune response against cancer. Some of these agents affect specific parts of the immune system, whereas others affect the immune system in a more general way.

The most widely prescribed and efficacious single-agent immuno-oncology antibody therapies that have been discovered and successfully developed to date are PD-(L)1 (programmed cell death protein 1 and programmed death-ligand 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4)  monoclonal antibodies. In addition to PD-(L)1 and CTLA-4, there are also a number of other immune checkpoints that are being explored in clinical trials.

In this publication, we will discuss PD1 (programmed cell death protein 1) and PDL1s (programmed death-ligand 1) immunotherapy.

TCR – T-cell receptors, APC – antigen-presenting cells, MHC – major histocompatibility complex, Ag – antigens,

Mechanism of Action MOA

PD-1 is a protein located on the surface of T-cells and is one of the proteins commonly referred to as an “immune checkpoint”. The general function of PD-1 is to prevent the T-cell mediated immune response from attacking normal cells in the body when certain proteins called PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2) on the surface of a normal cell bind to it.

Some cancer cells can express high levels of PD-L1 and PD-L2 to bind to the PD-1 on T-cells and thereby help the cancer cells evade T-cell attacks. PD-(L)1 antibody bind to PD-1 or PD-L1 and blocks PD-1 from binding to PD-L1 and/or PD-L2. This prevents the PD-1 found on T-cells from binding with the PD-L1 and/or PD-L2 found on cancer cells, which allows the T-cells to kill the cancer cells.

Immunotherapy has demonstrated success in some cancer types, such as Hodgkin’s lymphoma where the response rate is in the 80-90% range, the average response to anti-PD-(L)1 blockade is only around 15-20% in an all-comer population. (CLSA, 10 December 2019) Many solid tumors have low response rates, including some of the high incidences: gastric, head and neck squamous cell carcinoma, hepatocellular carcinoma, ovarian, cervical, biliary tract, esophageal, triple-negative breast cancer, and Non-Small Cell Lung Cancer – Non-Squamous (“NSCLC”), as shown in the below figure.

ORR – Overall Response Rate. Source: CLSA, British Journal of Cancer, 10th Dec 2019. MCC – Merkel cell carcinoma, Skin SCC – Skin squamous cell carcinoma, DLBCL – Diffuse large B-cell lymphoma, RCC – Renal cell carcinoma, SCLC – small cell lung cancer, NSCLC – Nonsmall-cell lung carcinoma, TNBC – Triple-negative breast cancer, HCC – Hepatocellular carcinoma, HNSCC – Head and neck squamous cell carcinoma, ER+ BC – Estrogen receptor Positive Breast Cancer

Globally, there are currently three PD-1 mAbs (monoclonal antibodies) approved by the US-FDA (US Food and Drug Administration) for 17 cancer indications, and three PD-L1 mAbs for six approved cancer indications. In China, there are currently six PD-1 mAbs and one PD-L1 mAb approved by NMPA(National Medical Products Administration). (Source: Akeso Inc IPO prospectus, April 2020).

PD1 is becoming the cornerstone of treatment – Example of stage IV NSCLC (Non-Small Cell Lung Cancer – Non-Squamous)

Of all types, lung cancer is the largest oncological indication, with 2.09 million patients per year globally, in 2018. (CLSA, 30 June 2020)_

Globally, PD1 is now considered a standard of care for late stage NSCLC (for patients without any driver gene mutations). As seen in the below chart, if patients have actionable drivers, they are typically given targeted, small-molecule therapies, while among patients without actionable driver mutations (those responsive to targeted therapies), the cornerstone treatment is Keytruda (pembrolizumab1) based programs.

Combination therapy

There is growing recognition in the academic and industry community that immuno-oncology combination therapies that simultaneously employ different mechanisms of action often display improvement in response rate and durability as compared to single-agent immunotherapies. Therefore, we believe that immuno-oncology combination therapies, especially combinations of two or more targeted therapies, are expected to be one of the future trends of oncology therapies.

With clinical evidence of synergy between PD-(L)1 agents and CTLA-4 agents, PD-(L)1 and CTLA-4 combination therapy has in recent years generated tremendous interests from the pharmaceutical industry. Examples of combination therapies include:

  • Dual T Checkpoint Inhibitors, eg. PD-1 or PD-L1 together with, CTLA-4, LAG-3 (Lymphocyte-activation gene 3), TIM-3 (T-cell immunoglobulin and mucin domain-3)
  • Checkpoint Inhibitors + Costimulatory Receptor Agonists
  • Costimulatory Receptor Agonists + Immunomodulators
  • Checkpoint Inhibitors + Target Therapy, eg. VEGFR (vascular endothelial growth factor)
  • Checkpoint Inhibitors + Immunomodulators/suppressor
  • Checkpoint inhibitors + Other Immune System Activators, eg. chemo, IL-2 (Interleukin-2), Vaccines

Beyond PD1s

As immune checkpoint inhibitors become the standard-of-care in many indications, such as lung cancer, more and more patients are progressing through these therapies, creating the need for treatment beyond PD-1/PDL1s.

There are several links in the immune cancer cycle that offer potential targets for immune-therapy. PD-1 agents target the last step, the killing of cancer cells, while CTLA-4 class of agents target priming and activation.

Immunotherapy: a New Approach of Cancer Treatment

Immunotherapy is a type of oncology treatment that helps the immune system fight cancer. The immune system helps the body fight infections and other diseases. Immunotherapy is a type of biological therapy. Biological therapy is a type of treatment that uses substances made of living organisms to treat cancer.

Immuno-oncology therapy, including checkpoint inhibitors, therapeutic cancer vaccines, cytokines and cell therapies, has revolutionized cancer treatment in the past few years. There is still significant room for improvement in immuno-oncology therapy’s efficacy and safety. Continued research and development efforts are underway around the world, with a focus on characterizing novel immuno-oncology targets and exploring combination therapies.

Given the substantial number of cancer patient population in China and the US, the global market size for immuno-oncology therapies is projected to continue growth at a substantial rate both domestically in China and abroad.

Several types of immunotherapy are used to treat cancer. These include:

  • Immune checkpoint inhibitors, which are drugs that block immune checkpoints. These checkpoints are a normal part of the immune system and keep immune responses from becoming too strong. By blocking them, these drugs allow immune cells to respond more powerfully against cancer.
  • T-cell transfer therapy, which is a treatment that boosts the natural ability of T cells to fight cancer. Those that are most active against cancer are selected or modified in the lab to better attack cancer cells.
  • Monoclonal antibodies, which are immune system proteins created in the lab, are designed to bind to specific targets on cancer cells. Some monoclonal antibodies mark cancer cells so that they can be better identified and destroyed by the immune system.
  • Treatment vaccines, which work against cancer by boosting the immune system’s response to cancer cells. Treatment vaccines are different from the ones that help prevent disease.
  • Immune system modulators, enhance the body’s immune response against cancer. Some of these agents affect specific parts of the immune system, whereas others affect the immune system in a more general way.

The most widely prescribed and efficacious single-agent immuno-oncology antibody therapies that have been discovered and successfully developed to date are PD-(L)1 (programmed cell death protein 1 and programmed death-ligand 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4)  monoclonal antibodies. In addition to PD-(L)1 and CTLA-4, there are also a number of other immune checkpoints that are being explored in clinical trials.

In this publication, we will discuss PD1 (programmed cell death protein 1) and PDL1s (programmed death-ligand 1) immunotherapy.

TCR – T-cell receptors, APC – antigen-presenting cells, MHC – major histocompatibility complex, Ag – antigens,

Mechanism of Action MOA

PD-1 is a protein located on the surface of T-cells and is one of the proteins commonly referred to as an “immune checkpoint”. The general function of PD-1 is to prevent the T-cell mediated immune response from attacking normal cells in the body when certain proteins called PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2) on the surface of a normal cell bind to it.

Some cancer cells can express high levels of PD-L1 and PD-L2 to bind to the PD-1 on T-cells and thereby help the cancer cells evade T-cell attacks. PD-(L)1 antibody bind to PD-1 or PD-L1 and blocks PD-1 from binding to PD-L1 and/or PD-L2. This prevents the PD-1 found on T-cells from binding with the PD-L1 and/or PD-L2 found on cancer cells, which allows the T-cells to kill the cancer cells.

Immunotherapy has demonstrated success in some cancer types, such as Hodgkin’s lymphoma where the response rate is in the 80-90% range, the average response to anti-PD-(L)1 blockade is only around 15-20% in an all-comer population. (CLSA, 10 December 2019) Many solid tumors have low response rates, including some of the high incidences: gastric, head and neck squamous cell carcinoma, hepatocellular carcinoma, ovarian, cervical, biliary tract, esophageal, triple-negative breast cancer, and Non-Small Cell Lung Cancer – Non-Squamous (“NSCLC”), as shown in the below figure.

ORR – Overall Response Rate. Source: CLSA, British Journal of Cancer, 10th Dec 2019. MCC – Merkel cell carcinoma, Skin SCC – Skin squamous cell carcinoma, DLBCL – Diffuse large B-cell lymphoma, RCC – Renal cell carcinoma, SCLC – small cell lung cancer, NSCLC – Nonsmall-cell lung carcinoma, TNBC – Triple-negative breast cancer, HCC – Hepatocellular carcinoma, HNSCC – Head and neck squamous cell carcinoma, ER+ BC – Estrogen receptor Positive Breast Cancer

Globally, there are currently three PD-1 mAbs (monoclonal antibodies) approved by the US-FDA (US Food and Drug Administration) for 17 cancer indications, and three PD-L1 mAbs for six approved cancer indications. In China, there are currently six PD-1 mAbs and one PD-L1 mAb approved by NMPA(National Medical Products Administration). (Source: Akeso Inc IPO prospectus, April 2020).

PD1 is becoming the cornerstone of treatment – Example of stage IV NSCLC (Non-Small Cell Lung Cancer – Non-Squamous)

Of all types, lung cancer is the largest oncological indication, with 2.09 million patients per year globally, in 2018. (CLSA, 30 June 2020)_

Globally, PD1 is now considered a standard of care for late stage NSCLC (for patients without any driver gene mutations). As seen in the below chart, if patients have actionable drivers, they are typically given targeted, small-molecule therapies, while among patients without actionable driver mutations (those responsive to targeted therapies), the cornerstone treatment is Keytruda (pembrolizumab1) based programs.

Combination therapy

There is growing recognition in the academic and industry community that immuno-oncology combination therapies that simultaneously employ different mechanisms of action often display improvement in response rate and durability as compared to single-agent immunotherapies. Therefore, we believe that immuno-oncology combination therapies, especially combinations of two or more targeted therapies, are expected to be one of the future trends of oncology therapies.

With clinical evidence of synergy between PD-(L)1 agents and CTLA-4 agents, PD-(L)1 and CTLA-4 combination therapy has in recent years generated tremendous interests from the pharmaceutical industry. Examples of combination therapies include:

  • Dual T Checkpoint Inhibitors, eg. PD-1 or PD-L1 together with, CTLA-4, LAG-3 (Lymphocyte-activation gene 3), TIM-3 (T-cell immunoglobulin and mucin domain-3)
  • Checkpoint Inhibitors + Costimulatory Receptor Agonists
  • Costimulatory Receptor Agonists + Immunomodulators
  • Checkpoint Inhibitors + Target Therapy, eg. VEGFR (vascular endothelial growth factor)
  • Checkpoint Inhibitors + Immunomodulators/suppressor
  • Checkpoint inhibitors + Other Immune System Activators, eg. chemo, IL-2 (Interleukin-2), Vaccines

Beyond PD1s

As immune checkpoint inhibitors become the standard-of-care in many indications, such as lung cancer, more and more patients are progressing through these therapies, creating the need for treatment beyond PD-1/PDL1s.

There are several links in the immune cancer cycle that offer potential targets for immune-therapy. PD-1 agents target the last step, the killing of cancer cells, while CTLA-4 class of agents target priming and activation.

AUTHORED BY
Saniel Chandrawat
Senior Investment Analyst – Healthcare, Energy, Utilities

Date: February 16, 2021
Category: Biotechnology, Themes & Insights

1 Pembrolizumab is an antibody used in cancer immunotherapy

The mentioned companies are strictly for educational and fund marketing purposes only. For more information on our product offering, please refer to our website.

This document is intended for Hong Kong investors only. This material is neither an offer to sell nor solicitation to buy a security to any person in any jurisdiction where such solicitation, offer, purchase or sale would be unlawful under the laws of that jurisdiction. Investment involves risk.
The information in this material is based on sources we believe to be reliable but we do not guarantee the accuracy of completeness of the information provided. This material has not been reviewed by SFC and shall only be circulated in countries where it is permitted.
This material is intended solely for your private use and shall not be reproduced or recirculated either in whole or in part, without the written permission of Mirae Asset Global Investments. This document has been prepared for presentation, illustration and discussion purposes only and is not legally binding. Whilst compiled from sources Mirae Asset Global Investments believes to be accurate, no representation, warranty, assurance or implication to the accuracy, completeness or adequacy from defect of any kind is made. The division, group, subsidiary or affiliate of Mirae Asset Global Investments which produced this document shall not be liable to the recipient or controlling shareholders of the recipient resulting from its use. The views and information discussed or referred in this report are as of the date of publication, are subject to change and may not reflect the current views of the writer(s). The views expressed represent an assessment of market conditions at a specific point in time, are to be treated as opinions only and should not be relied upon as investment advice regarding a particular investment or markets in general. In addition, the opinions expressed are those of the writer(s) and may differ from those of other Mirae Asset Global Investments’ investment professionals.
The provision of this document shall not be deemed as constituting any offer, acceptance, or promise of any further contract or amendment to any contract which may exist between the parties. The issuer of this article is Mirae Asset Global Investments (HK) Limited (“we”) which we may or our managed funds may hold the mentioned securities. It should not be distributed to any other party except with the written consent of Mirae Asset Global Investments. Nothing herein contained shall be construed as granting the recipient whether directly or indirectly or by implication, any license or right, under any copy right or intellectual property rights to use the information herein. This document may include reference data from third-party sources and Mirae Asset Global Investments has not conducted any audit, validation, or verification of such data. Mirae Asset Global Investments accepts no liability for any loss or damage of any kind resulting out of the unauthorized use of this document. Investment involves risk. Past performance figures are not indicative of future performance. Forward-looking statements are not guarantees of performance. The information presented is not intended to provide specific investment advice. Please carefully read through the offering documents and seek independent professional advice before you make any investment decision. Products, services, and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries, and/or distributors of Mirae Asset Global Investments as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.
Hong Kong: This material is prepared by Mirae Asset Global Investments (HK) Limited (Mirae HK). Mirae HK is regulated by the SFC (CE reference: ALK083).
Australia: The information contained on this document is provided by Mirae Asset Global Investments (HK) Limited (“MAGIHK”), which is exempt from the requirement to hold an Australian financial services license under the Corporations Act 2001 (Cth) (Corporations Act) pursuant to ASIC Class Order 03/1103 (Class Order) in respect of the financial services it provides to wholesale clients (as defined in the Corporations Act) in Australia. MAGIHK is regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws, which differ from Australian laws. Pursuant to the Class Order, this document and any information regarding MAGIHK and its products is strictly provided to and intended for Australian wholesale clients only. By accessing this document and any information or content contained in it, you represent that you are a ‘wholesale client’ under the Corporations Act. This document is strictly for information purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. Further, this document should not be regarded by investors as a substitute for independent professional advice or the exercise of their own judgement. The contents of this document is prepared and maintained by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Australian Investments & Securities Commission. No part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGI HK. Copyright 2020. All rights reserved.